Products for the treatment of inflammatory bowel disease: a patent review (2013 – 2014)

Bibliography

• Ghosh S, Pariente B, Mould DR, et al. New tools and approaches for improved management of inflammatory bowel diseases. J Crohns Colitis 2014;8(10):1246-53
   PubMed Web of Science ®Google Scholar
• Aloi M, Nuti F, Stronati L, et al. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol 2014;11(2):99-108
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474(7351):298-306
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411(6837):603-6
   PubMed Web of Science ®Google Scholar
• Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013;5:237-47
   PubMedGoogle Scholar
• Gisbert JP, Domenech E. Vedolizumab in the treatment of Crohn’s disease. Gastroenterol Hepatol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut 2011;60(12):1754-63
   PubMed Web of Science ®Google Scholar
• Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013;9(1):77-92
   PubMed Web of Science ®Google Scholar
• Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014;147(5):981-9
   PubMed Web of Science ®Google Scholar
• Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 2014;7:113-20
   PubMedGoogle Scholar
• Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2014; Epub ahead of print
   Web of Science ®Google Scholar
• D’Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56(5):725-32
   PubMed Web of Science ®Google Scholar
• Forbes W, Borte E, Johnson L, et al. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males. Salix Pharmaceuticals, Ltd. US8497256B2; 2013
   Google Scholar
• Pravda J. Methods for treatment for ulcerative colitis in mammals. Therapeutic Research, LLC. USPTO8476233; 2013
   Google Scholar
• Lichtenberger LM. Preparations of pharmaceuticals containing 5-amino salicylic acid and phospholipids for treatment of inflammatory bowel disease. Board Of Regents Of The University Of Texas System. JPO2014015478; 2014
   Google Scholar
• Wolfe HRE. Therapeutic peptides. Combimab, Inc. USPTO8748575; 2014
   Google Scholar
• Shailubhai K. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders. Synergy Pharmaceuticals Inc. USPTO8569246; 2013
   Google Scholar
• Pitari GM. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther 2013;7:351-60
   PubMed Web of Science ®Google Scholar
• Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
   PubMed Web of Science ®Google Scholar
• Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9(4):403-10
   PubMed Web of Science ®Google Scholar
• Guarino A, Cohen MB, Giannella RA. Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr Res 1987;21(6):551-5
   PubMed Web of Science ®Google Scholar
• Waldman SA, O’Hanley P, Falkow S, et al. A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli. J Infect Dis 1984;149(1):83-9
   PubMed Web of Science ®Google Scholar
• Han X, Mann E, Gilbert S, et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One 2011;6(1):e16139
   PubMed Web of Science ®Google Scholar
• Lin JE, Snook AE, Li P, et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One 2012;7(2):e31686
   PubMed Web of Science ®Google Scholar
• Barbera Betancourt A, del Carmen Dominguez Horta M, Lorenzo Perez N, et al. Method of inducing T cell apoptosis by administering Altered Peptide Ligand. Cuba; Centro de Ingenieria Genetica y Biotecnologia. USPTO8410057; 2013
   Google Scholar
• Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med (Berl) 2001;79(10):552-65
   PubMed Web of Science ®Google Scholar
• Paterson B, Tamiz A, Pandey N, et al. Use of tight junction antagonists to treat inflammatory bowel disease. Alba Therapeutics Corp. USPTO8796203; 2014
   Google Scholar
• Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci 2012;1258:25-33
   PubMed Web of Science ®Google Scholar
• Vanuytsel T, Vermeire S, Cleynen I. The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. Tissue Barriers 2013;1(5):e27321
   PubMedGoogle Scholar
• Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009;58(1):41-8
   PubMed Web of Science ®Google Scholar
• Wu TC. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease. Holy Stone Healthcare Co., Ltd. USPTO8575130; 2013
   Google Scholar
• Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006;85(8):699-715
   PubMed Web of Science ®Google Scholar
• Xu YZ, Yuan S, Wone D, et al. Pyridinone antagonists of alpha-4 integrins. Elan Pharmaceuticals, Inc. USPTO8367836; 2013
   Google Scholar
• Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des 2002;8(14):1229-53
   PubMed Web of Science ®Google Scholar
• Greene MI, Hancock MW, Katsumata M, et al. Therapy of autoimmune colitis using a TIP60 inhibitor. The Trustees Of The University Of Pennsylvania, The Children’s Hospital of Philadelphia. USPTO8497285; 2013
   Google Scholar
• Xiao Y, Nagai Y, Deng G, et al. Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60. Cell Rep 2014;7(5):1471-80
   PubMed Web of Science ®Google Scholar
• DeLuca HF, Clagett-Dame M, Plum LA, et al. A-ring modified 19-nor-vitamin D analogs and their uses. Wisconsin Alumni Research Foundation. USPTO8785422; 2014
   Google Scholar
• Ganapathy V, Prasad PD, Martindale RG, et al. Prodrugs of short-chain fatty acids and treatment methods. Georgia Health Sciences University Research Institute, Inc. USPTO8518989; 2013
   Google Scholar
• Haller D, Hormannsperger G. Lactocepins for use in the treatment of IP-10-mediated inflammatory diseases. Technische Universitat Munchen. WO0209411; 2013
   Google Scholar
• Tracey KJ, Wang H. Inhibition of inflammation using α7 receptor-binding cholinergic agonist. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014
   Google Scholar
• Yamamuro N, Nakamaru K, Yasue T. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014
   Google Scholar
• Takanao O. Hirotsugu c/o Astellas Pharma Inc; UEDA, Keiko c/o Astellas Pharma Inc. Compound WS727713. Telsar Pharma Inc. JPO2014040456; 2014
   Google Scholar
• Yamamoto A, Nasu R, Ito Y. Composition for preventing and/or treating colonic inflammatory disease. Kaigen Pharma Co. Ltd. JPO2014009179; 2014
   Google Scholar
• Tsutsumi Y, Yoshioka Y, Yoshikawa T, et al. Preventive or therapeutic agent for inflammatory bowel disease. Vitamin C60 Bioresearch Kk. Osaka Univ. JPO2013087108; 2013
   Google Scholar
• Sheridan H, Frankish N. Indene derivatives for use in the treatment of inflammatory bowel disease. Venantius Ltd. EP2734496A1; 2013
   Google Scholar
• Eussen SR, Verhagen H, Klungel OH, et al. Functional foods and dietary supplements: products at the interface between pharma and nutrition. Eur J Pharmacol 2011;668(Suppl 1):S2-9
   PubMed Web of Science ®Google Scholar
• Roberfroid M. Functional food concept and its application to prebiotics. Dig Liver Dis 2002;34(Suppl 2):S105-10
   PubMedGoogle Scholar
• Diplock AT, Ashwell M, Bomet F, et al. Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 1999;81(Suppl 1):S1-27
   PubMed Web of Science ®Google Scholar
• Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009;15(3):454-62
   PubMed Web of Science ®Google Scholar
• Toumi R, Soufli I, Rafa H, et al. Probiotic bacteria lactobacillus and bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice. Int J Immunopathol Pharmacol 2014;27(4):615-27
   PubMed Web of Science ®Google Scholar
• Elian SD, Souza EL, Vieira AT, et al. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. Benef Microbes 2015;6(3):277-86
   PubMed Web of Science ®Google Scholar
• Shadnoush M, Shaker Hosseini R, Mehrabi Y, et al. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. Iran J Pharm Res 2013;12(4):929-36
   PubMed Web of Science ®Google Scholar
• Lorea Baroja M, Kirjavainen PV, Hekmat S, et al. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007;149(3):470-9
   PubMed Web of Science ®Google Scholar
• Viladomiu M, Hontecillas R, Yuan L, et al. Nutritional protective mechanisms against gut inflammation. J Nutr Biochem 2013;24(6):929-39
   PubMed Web of Science ®Google Scholar
• Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol 2014;20(33):11505-24
   PubMed Web of Science ®Google Scholar
• Borchers AT, Selmi C, Meyers FJ, et al. Probiotics and immunity. J Gastroenterol 2009;44(1):26-46
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125(6):1401-12
   PubMed Web of Science ®Google Scholar
• Roberfroid MB. Fructo-oligosaccharide malabsorption: benefit for gastrointestinal functions. Curr Opin Gastroenterol 2000;16(2):173-7
   PubMed Web of Science ®Google Scholar
• Tojo R, Suarez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014;20(41):15163-76
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang H, Wang Y, et al. Acetylation and carboxymethylation of the polysaccharide from Ganoderma atrum and their antioxidant and immunomodulating activities. Food Chem 2014;156:279-88
   PubMed Web of Science ®Google Scholar
• Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc 2014;73(4):490-7
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013;2013:435268
   PubMed Web of Science ®Google Scholar
• Yu CG, Huang Q. Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. J Dig Dis 2013;14(10):513-17
   PubMed Web of Science ®Google Scholar
• Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol 2013;48(3):315-21
   PubMed Web of Science ®Google Scholar
• Wu GD, Bushmanc FD, Lewis JD. Diet, the human gut microbiota, and IBD. Anaerobe 2013;24:117-20
   PubMed Web of Science ®Google Scholar
• Roy CC, Kien CL, Bouthillier L, et al. Short-chain fatty acids: ready for prime time? Nutr Clin Pract 2006;21(4):351-66
   PubMedGoogle Scholar
• Hu GX, Chen GR, Xu H, et al. Activation of the AMP activated protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect of a high fiber diet on the metabolic syndrome. Med Hypotheses 2010;74(1):123-6
   PubMed Web of Science ®Google Scholar
• den Besten G, van Eunen K, Groen AK, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013;54(9):2325-40
   PubMed Web of Science ®Google Scholar
• Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011;13(5):517-26
   PubMed Web of Science ®Google Scholar
• Blouin JM, Penot G, Collinet M, et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer 2011;128(11):2591-601
   PubMed Web of Science ®Google Scholar
• Tang Y, Chen Y, Jiang H, et al. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 2011;128(4):847-56
   PubMed Web of Science ®Google Scholar
• Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008;27(2):104-19
   PubMed Web of Science ®Google Scholar
• Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990;70(2):567-90
   PubMed Web of Science ®Google Scholar
• Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83(2):424-9
   PubMed Web of Science ®Google Scholar
• Vinolo MA, Rodrigues HG, Hatanaka E, et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 2011;22(9):849-55
   PubMed Web of Science ®Google Scholar
• Soldavini J, Kaunitz JD. Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig Dis Sci 2013;58(10):2756-66
   PubMed Web of Science ®Google Scholar
• Bringiotti R, Ierardi E, Lovero R, et al. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014;5(4):550-9
   PubMedGoogle Scholar
• Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl Microbiol 2004;54:261-89
   PubMed Web of Science ®Google Scholar
• Raso E, Lapis K. Use of fermented wheat germ in the treatment of inflammatory bowel disease. 3 CH Ltd., Raso, Erzsebet; Lapis, Karoly. WO2012159988; 2014
   Google Scholar
• Demidov LV, Manziuk LV, Kharkevitch GY, et al. Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. Cancer Biother Radiopharm 2008;23(4):477-82
   PubMed Web of Science ®Google Scholar
• Balint G, Apathy A, Gaal M, et al. Effect of Avemar–a fermented wheat germ extract–on rheumatoid arthritis. Preliminary data. Clin Exp Rheumatol 2006;24(3):325-8
   PubMed Web of Science ®Google Scholar
• Farkas E. Fermented wheat germ extract in the supportive therapy of colorectal cancer. Orv Hetil 2005;146(37):1925-31
   PubMedGoogle Scholar
• Jakab F, Shoenfeld Y, Balogh A, et al. A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 2003;89(3):465-9
   PubMed Web of Science ®Google Scholar
• Jakab F, Mayer A, Hoffmann A, et al. First clinical data of a natural immunomodulator in colorectal cancer. Hepatogastroenterology 2000;47(32):393-5
   PubMed Web of Science ®Google Scholar
• Sukkar S, Cella F, Rovera G, et al. A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar). Mediterr J Nutr Metab 2008;1(1):37-42
   Google Scholar
• MacSharry J, O’Mahony L, O’Sullivan D, et al. Probiotic bifidobacterium strains. Alimentary Heath Ltd. USPTO8557233; 2013
   Google Scholar
• Mojca Lunder L, Ravnikar M, Strukelj B, et al. Modified food grade microorganism for treatment of inflammatory bowel disease. University of Ljubljana; Institute Jozef Stefan; Labena d.o.o. US8754198B2; 2014
   Google Scholar
• Veiga P, Chambaud I, Khlebnikov A, et al. Method for reducing gastro-intestinal inflammation using Bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria. Compagnie Gervais Danone; President and Fellows of Harvard College. USPTO8685388; 2014
   Google Scholar
• Guyonnet D, Schlumberger A, Mhamdi L, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009;102(11):1654-62
   PubMed Web of Science ®Google Scholar
• Veiga P, Gallini CA, Beal C, et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci USA 2010;107(42):18132-7
   PubMed Web of Science ®Google Scholar
• Israelsen H. Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effector. Nordisk Rebalance As. JPO2013144712; 2013
   Google Scholar
• Krag A, Munkholm P, Israelsen H, et al. Profermin is efficacious in patients with active ulcerative colitis–a randomized controlled trial. Inflamm Bowel Dis 2013;19(12):2584-92
   PubMed Web of Science ®Google Scholar
• Krag A, Israelsen H, von Ryberg B, et al. Safety and efficacy of Profermin(R) to induce remission in ulcerative colitis. World J Gastroenterol 2012;18(15):1773-80
   PubMed Web of Science ®Google Scholar
• Daisuke M, Asama T, Motoki H, et al. New lactic acid bacteria having promotion activity for IgA production and use of the same. Yamada Bee Co., Inc. JPO2014073130; 2013
   Google Scholar
• Saburo M, Tomohiro O, Hiroyuki S, et al. Inflammatory bowel disease inhibitor, and food and drink. Tottori Univaon Chemical Kkota Suten:Kktottori Institute of Industrial Technology. JPO2013180958; 2013
   Google Scholar
• Wakuda T, Azuma K, Saimoto H, et al. Protective effects of galacturonic acid-rich vinegar brewed from Japanese pear in a dextran sodium sulfate-induced acute colitis model. J Funct Foods 2013;5(1):516-23
   Web of Science ®Google Scholar
• Raine T. Vedolizumab for inflammatory bowel disease: changing the game, or more of the same? United European Gastroenterol J 2014;2(5):333-44
   PubMed Web of Science ®Google Scholar
• Zampeli E, Gizis M, Siakavellas SI, et al. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014;5(3):293-303
   PubMedGoogle Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61(6):918-32
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn’s disease. BioDrugs 2015;29(1):57-67
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7(8):636-43
   PubMed Web of Science ®Google Scholar
• McKenzie ANJ, Neill D. Antibodies against IL-17BR. Medical Research Council. USPTO8586037; 2013
   Google Scholar
• Camelo A, Barlow JL, Drynan LF, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol 2012;47(11):1198-211
   PubMed Web of Science ®Google Scholar
• Saadoun D, Terrier B, Cacoub P. Interleukin-25: key regulator of inflammatory and autoimmune diseases. Curr Pharm Des 2011;17(34):3781-5
   PubMed Web of Science ®Google Scholar
• Monteleone G, Pallone F, Macdonald TT. Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev 2010;21(6):471-5
   PubMed Web of Science ®Google Scholar
• Shibuya A, Oda C, Iino S, et al. Medicine comprising active modulator of CD300a-expressing cell associated with inflammatory bowel disease, CD300aa gene knock-out mouse, and use of active modulator of CD300a-expressing cell. University of Tsukuba. JPO2014094898; 2014
   Google Scholar
• DeBell KE, Simhadri VR, Mariano JL, et al. Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a. BMC Immunol 2012;13:23
   PubMed Web of Science ®Google Scholar
• Tanaka T, Tahara-Hanaoka S, Nabekura T, et al. PPARbeta/delta activation of CD300a controls intestinal immunity. Sci Rep 2014;4:5412
   PubMed Web of Science ®Google Scholar
• Pickford LB, Bebbington CR, Yarranton GT, et al. Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist. Medarex, L.L.C. USPTO8828393; 2014
   Google Scholar
• Monteleone G, Pender SL, Alstead E, et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001;48(3):425-9
   PubMed Web of Science ®Google Scholar
• Fais S, Capobianchi MR, Silvestri M, et al. Interferon expression in Crohn’s disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994;14(5):235-8
   PubMedGoogle Scholar
• Kole A, He J, Rivollier A, et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol 2013;191(5):2771-9
   PubMed Web of Science ®Google Scholar
• Cho H, Kelsall BL. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev 2014;260(1):145-67
   PubMed Web of Science ®Google Scholar
• Monteleone G. Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field. Nogra Pharma Ltd. USPTO8648186; 2014
   Google Scholar
• Zorzi F, Angelucci E, Sedda S, et al. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig Liver Dis 2013;45(7):552-5
   PubMedGoogle Scholar
• Monteleone G, Caruso R, Pallone F. Role of Smad7 in inflammatory bowel diseases. World J Gastroenterol 2012;18(40):5664-8
   PubMed Web of Science ®Google Scholar
• Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther 2012;20(4):870-6
   PubMed Web of Science ®Google Scholar
• Frey MR. Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis. Children’s Hospital Los Angeles. EP2744512A1; 2013
   Google Scholar
• Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008;65(10):1566-84
   PubMed Web of Science ®Google Scholar
• Bernard JK, McCann SP, Bhardwaj V, et al. Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo. J Biol Chem 2012;287(47):39850-8
   PubMed Web of Science ®Google Scholar
• McElroy SJ, Castle SL, Bernard JK, et al. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis. Am J Pathol 2014;184(10):2768-78
   PubMed Web of Science ®Google Scholar
• Weinstock JV, Elliot DE. Use of parasitic biological agents for prevention and control of autoimmune diseases. University of Iowa Research Foundation. JPO2014129390; 2014
   Google Scholar
• Chen NJ, Huang MW, Hsieh SL. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. J Immunol 2001;166(1):270-6
   PubMed Web of Science ®Google Scholar
• Heylen M, Ruyssers NE, Gielis EM, et al. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 2014;143(2):153-67
   PubMed Web of Science ®Google Scholar
• Grzych JM, Pearce E, Cheever A, et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol 1991;146(4):1322-7
   PubMed Web of Science ®Google Scholar
• Oswald IP, Caspar P, Jankovic D, et al. IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 1994;153(4):1707-13
   PubMed Web of Science ®Google Scholar
• Zhang C, Li Y, Xu Y, et al. Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases. Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Chenggang Zhang, Junhuai LI, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li, Institute Of Radiation Medicine, Academy Of Military Medical Sciences, People’s Liberation Army Of China. EP2730287A1; 2013
   Google Scholar
• Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167(3):1609-16
   PubMed Web of Science ®Google Scholar
• Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113(9):1296-306
   PubMed Web of Science ®Google Scholar